(Q79610880)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17237929%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

title

[Omalizumab as a therapeutic option in atopic eczema. Current evidence and potential benefit] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17237929%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

author name string

J Schmitt

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17237929%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

K Schäkel

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17237929%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

publication date

1 February 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17237929%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17237929%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

volume

58

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17237929%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17237929%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

page(s)

128, 130-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17237929%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00105-006-1280-y

24 December 2019

exact match

0 references

cites work

Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis

1 reference

12 December 2020

Wanted: A study with omalizumab to determine the role of IgE-mediated pathways in atopic dermatitis

1 reference

12 December 2020

Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

1 reference

12 December 2020

Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.

1 reference

12 December 2020

Systemic treatment of severe atopic eczema: a systematic review

1 reference

12 December 2020

Effect of omalizumab in health care workers with occupational latex allergy.

1 reference

12 December 2020

Failure of omalizumab for treatment of severe adult atopic dermatitis

1 reference

12 December 2020

Efficacy of anti-IgE therapy in patients with atopic dermatitis

1 reference

12 December 2020

Engagement of the Fc epsilon RI stimulates the production of IL-16 in Langerhans cell-like dendritic cells

1 reference

12 December 2020

Peripheral blood dendritic cells express Fc epsilon RI as a complex composed of Fc epsilon RI alpha- and Fc epsilon RI gamma-chains and can use this receptor for IgE-mediated allergen presentation

1 reference

12 December 2020

Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.

1 reference

12 December 2020

The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation

1 reference

12 December 2020

Unanswered clinical questions and speculation about the role of anti-immunoglobulin E in atopic and nonatopic disease

1 reference

12 December 2020

Treatment of recalcitrant atopic dermatitis with omalizumab

1 reference

12 December 2020

10.1007/S00105-006-1280-Y

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17237929%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference